Literature DB >> 21404127

Making a case to continue considering treatment with selective serotonin reuptake inhibitors for children with autism spectrum disorders.

Wendy Froehlich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21404127     DOI： 10.1007/s11920-011-0196-0

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  9 in total

1.  Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.

Authors:  Yoko Sugie; Hideo Sugie; Tokiko Fukuda; Masataka Ito; Yumiko Sasada; Mutsumi Nakabayashi; Kazunobu Fukashiro; Takehiko Ohzeki
Journal:  J Autism Dev Disord       Date:  2005-06

Review 2.  Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues.

Authors:  F Volkmar; E H Cook; J Pomeroy; G Realmuto; P Tanguay
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1999-12       Impact factor: 8.829

Review 3.  Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).

Authors:  Katrina Williams; Danielle M Wheeler; Natalie Silove; Philip Hazell
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

4.  Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study.

Authors:  M S Buchsbaum; E Hollander; M M Haznedar; C Tang; J Spiegel-Cohen; T C Wei; A Solimando; B R Buchsbaum; D Robins; C Bienstock; C Cartwright; S Mosovich
Journal:  Int J Neuropsychopharmacol       Date:  2001-06       Impact factor: 5.176

5.  A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.

Authors:  Eric Hollander; Ann Phillips; William Chaplin; Karen Zagursky; Sherie Novotny; Stacey Wasserman; Rupa Iyengar
Journal:  Neuropsychopharmacology       Date:  2005-03       Impact factor: 7.853

6.  A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

Authors:  C J McDougle; S T Naylor; D J Cohen; F R Volkmar; G R Heninger; L H Price
Journal:  Arch Gen Psychiatry       Date:  1996-11

7.  Clinical and neurochemical effects of fenfluramine in children with autism.

Authors:  B L Leventhal; E H Cook; M Morford; A J Ravitz; W Heller; D X Freedman
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1993       Impact factor: 2.198

8.  Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

Authors:  Bryan H King; Eric Hollander; Linmarie Sikich; James T McCracken; Lawrence Scahill; Joel D Bregman; Craig L Donnelly; Evdokia Anagnostou; Kimberly Dukes; Lisa Sullivan; Deborah Hirtz; Ann Wagner; Louise Ritz
Journal:  Arch Gen Psychiatry       Date:  2009-06

9.  Urinary dopamine metabolites as indicators of the responsiveness to fenfluramine treatment in children with autistic behavior.

Authors:  C Barthelemy; N Bruneau; J Jouve; J Martineau; J P Muh; G Lelord
Journal:  J Autism Dev Disord       Date:  1989-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.